SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

IKT

Inhibikase Therapeutics Inc.
NASDAQHealth Care

Latest close: 1.65 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 8, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Aug 26, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  3. Aug 11, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record33521 flagged findings
Reported transactions (Form 4)50since Oct 21, 2024 · and 7 other holdings
Corporate events (8-K)30since Mar 8, 2022

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-12share offering or dilution eventrecentOpen filing ↗
    “…Accrued expenses and other current liabilities consist of the following: March 31, 2026 December 31, 2025 Accrued consulting…”
    +1 more passage from the same document
    • “…3 Part A interim 12 week safety readout for IKT-001 for PAH and (b) the Company both obtaining stockholder approval for and…”
  • 2026-05-12merger or acquisition eventrecentOpen filing ↗
    “…which expire on August 5, 2029. All of the warrants in the May 2024 Offering were issued to a single investor. All Pre-Funded…”
    +1 more passage from the same document
    • “…in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as…”
  • 2026-03-26share offering or dilution eventrecentOpen filing ↗
    “…we are eligible to receive development and regulatory milestone payments up to $47.5 million and double-digit royalty payments…”
    +1 more passage from the same document
    • “…from the issuance of common stock related to the exercise of stock options. Net cash provided by financing activities for the…”
  • 2026-03-26regulatory investigationrecentOpen filing ↗
    “…including closing our contract manufacturers’ facilities; • mandate modifications to promotional materials or require us to…”
  • 2026-03-26Department of Justice inquiryrecentOpen filing ↗
    “…We will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA and comparable foreign…”
    +1 more passage from the same document
    • “…remain to be adopted, and are not expected to become applicable before 2028. Other U.S. Regulatory Matters Manufacturing,…”
  • 2026-03-26merger or acquisition eventrecentOpen filing ↗
    “…of common stock ( “Common Stock”) on Nasdaq under the symbol “IKT.” Key recent operational and financing milestones are: • In…”
    +1 more passage from the same document
    • “…in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Reverse splits in 5 years

1 reverse split in 5 years (1:6 on Jun 30, 2023) · 1:6 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 335)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Sep 8, 268-K ↗Current report · Communication to the market
  • Aug 26, 268-K ↗Current report · Auditor change filing (8-K Item 4.01)
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Perceptive Advisors LLC · 6.9% · event on Jun 30, 26 · amendment
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Nantahala Capital Management, LLC · 4.3% · event on Jun 30, 26 · amendment
  • Aug 13, 26SCHEDULE 13G/A ↗Passive stake · Sands Capital Life Sciences Pulse Fund II, L.P. · 9.3% · event on Jun 30, 26 · amendment
  • Aug 11, 2610-Q ↗Quarterly report
  • Aug 11, 268-K ↗Current report · Results
  • Jul 31, 26SCHEDULE 13G/A ↗Passive stake · RA Capital Management, L.P. · 9.9% · event on Jul 29, 26 · amendment
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Jul 29, 268-K ↗Current report · Sold unregistered shares
  • Jul 28, 26SCHEDULE 13G ↗Passive stake · BlackRock, Inc. · 5.9% · event on Jun 30, 26
  • Jul 23, 268-K ↗Current report · Communication to the market
  • Jul 17, 26SCHEDULE 13G ↗Passive stake · RA Capital Management, L.P. · 15.9% · event on Jul 10, 26
  • Jul 17, 26Form 3 ↗Insider transaction
  • Jul 14, 268-K ↗Current report · Other events
  • Insider transaction · 6 Form 4 filingsshow all 6hide
  • Jun 29, 268-K ↗Current report · A senior executive left or was appointed
  • May 15, 26SCHEDULE 13G/A ↗Passive stake · Commodore Capital LP · 9.9% · event on Mar 31, 26 · amendment
  • May 15, 26SCHEDULE 13G/A ↗Passive stake · Trails Edge Capital Partners, LP · 6.1% · event on Mar 31, 26 · amendment

335 filings on record, the oldest from Sep 7, 18.

Listing the 25 most recent filings of the 335 on record.

8-Ks, explained

Stress2Structure17Governance13
  • Aug 26, 26GovernanceAuditor change filing (8-K Item 4.01)+1 more in the same filing8-K 4.01 ↗
  • Jul 29, 26StructureSold unregistered shares+1 more in the same filing8-K 3.02 ↗
  • Jun 29, 26GovernanceA senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
  • Nov 21, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Apr 14, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Feb 24, 25StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • Feb 18, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Dec 5, 24StructureA material agreement was terminated8-K 1.02 ↗
  • Oct 22, 24StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Oct 10, 24StructureEntered a material agreement+5 more in the same filing8-K 1.01 ↗
  • May 20, 24StructureSold unregistered shares+3 more in the same filing8-K 3.02 ↗
  • Apr 2, 24GovernanceA senior executive left or was appointed+1 more in the same filing8-K/A 5.02 ↗

10 older filings not shown · The record reaches back to Dec 29, 20.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

The full record holds 2 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • RA Capital Management, L.P.9.9%Jul 29, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Commodore Capital LP9.9%Mar 31, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • ADAR1 Capital Management, LLC9.9%Mar 31, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Fairmount Funds Management LLC9.9%Dec 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Sands Capital Life Sciences Pulse Fund II, L.P.9.3%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
show 4 more holdershide
  • Perceptive Advisors LLC6.9%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
  • Trails Edge Capital Partners, LP6.1%Mar 31, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • BlackRock, Inc.5.9%Jun 30, 26SCHEDULE 13G ↗
  • Nantahala Capital Management, LLC4.3%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Nov 21, 25Buy$3.0MSands Capital Life Sciences Pulse Fund II, L.P.↗
  • Oct 21, 24Buy$500KAmit Munshi↗
  • Oct 21, 24Buy$199KArvind Kush↗
  • Oct 21, 24Buy$2.0MRoberto Bellini↗
Stock compensation, tax and giftsshow the 6 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Jul 30, 26Compensation$28KDENNIS N BERMAN↗
  • Jul 29, 26Otheramount n/aRA CAPITAL MANAGEMENT, L.P.↗
  • Feb 21, 26Otheramount n/aAmit Munshi↗
  • Feb 21, 26Otheramount n/aChristopher CabellPresident & Head of R&D↗
  • Feb 21, 26Otheramount n/aVincent Aurentz↗
  • Feb 21, 25Compensationamount n/aAmit Munshi↗

The full record holds 10 transactions and goes back to Mar 1, 23.

Its sector and its market

Inhibikase Therapeutics Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Inhibikase Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Inhibikase Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
335 documents on file, from Sep 7, 2018 to Sep 8, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.